NDC 66267-112 Hydroxyzine Hydrochloride

Hydroxyzine Hydrochloride

NDC Product Code 66267-112

NDC CODE: 66267-112

Proprietary Name: Hydroxyzine Hydrochloride What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.

Non-Proprietary Name: Hydroxyzine Hydrochloride What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

Product Characteristics

Color(s):
WHITE (C48325)
Shape: ROUND (C48348)
Size(s):
7 MM
Imprint(s):
H;105
Score: 1

NDC Code Structure

NDC 66267-112-15

Package Description: 15 TABLET, FILM COATED in 1 BOTTLE

NDC 66267-112-30

Package Description: 30 TABLET, FILM COATED in 1 BOTTLE

NDC Product Information

Hydroxyzine Hydrochloride with NDC 66267-112 is a a human prescription drug product labeled by Nucare Pharmaceuticals, Inc.. The generic name of Hydroxyzine Hydrochloride is hydroxyzine hydrochloride. The product's dosage form is tablet, film coated and is administered via oral form. The RxNorm Crosswalk for this NDC code indicates a single RxCUI concept is associated to this product: 995218.

Dosage Form: Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Hydroxyzine Hydrochloride Active Ingredient(s)

What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.


Inactive Ingredient(s)

About the Inactive Ingredient(s)
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

  • LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
  • SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
  • HYPROMELLOSES (UNII: 3NXW29V3WO)
  • MAGNESIUM STEARATE (UNII: 70097M6I30)
  • CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)
  • SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)
  • STEARIC ACID (UNII: 4ELV7Z65AP)
  • POLYETHYLENE GLYCOLS (UNII: 3WJQ0SDW1A)
  • POLYSORBATE 80 (UNII: 6OZP39ZG8H)
  • TITANIUM DIOXIDE (UNII: 15FIX9V2JP)

Administration Route(s)

What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Oral - Administration to or by way of the mouth.

Pharmacological Class(es)

What is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

  • Antihistamine - [EPC] (Established Pharmacologic Class)
  • Histamine Receptor Antagonists - [MoA] (Mechanism of Action)

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Nucare Pharmaceuticals, Inc.
Labeler Code: 66267
FDA Application Number: ANDA040804 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Marketing Category: ANDA - A product marketed under an approved Abbreviated New Drug Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 06-30-2008 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2022 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N - NO What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".

* Please review the disclaimer below.

Information for Patients

Hydroxyzine

Hydroxyzine is pronounced as (hye drox' i zeen)

Why is hydroxyzine medication prescribed?
Hydroxyzine is used in adults and children to relieve itching caused by allergic skin reactions. It is also used alone or with other medications in adults and children to...
[Read More]

* Please review the disclaimer below.

Hydroxyzine Hydrochloride Product Label Images

Hydroxyzine Hydrochloride Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

Description

HydrOXYzine hydrochloride  has the chemical name of 2-[2-[4-  (p-Chloro-α-phenylbenzyl)-1-piperazinyl] ethoxy] ethanol dihydrochloride.HydrOXYzine hydrochloride occurs as a white, odorless powder which is very soluble in water.Each tablet for oral administration contains 10 mg, 25 mg or 50 mg hydrOXYzine HCl.  Inactive ingredients include: lactose monohydrate, colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, stearic acid, polyethylene glycol, polysorbate 80, and titanium dioxide.

Clinical Pharmacology

HydrOXYzine hydrochloride is unrelated chemically to the phenothiazines, reserpine, meprobamate or the benzodiazepines.  HydrOXYzine is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the central nervous system.Primary skeletal muscle relaxation has been demonstrated experimentally.  Bronchodilator activity, and antihistaminic and analgesic effects have been demonstrated experimentally and confirmed clinically.  An antiemetic effect, both by the apomorphine test and the veriloid test, has been demonstrated.Pharmacological and clinical studies indicate that hydrOXYzine in therapeutic dosage does not increase gastric secretion or acidity and in most cases has mild antisecretory activity.HydrOXYzine is rapidly absorbed from the gastrointestinal tract and hydrOXYzine’s clinical effects are usually noted within 15 to 30 minutes after oral administration.

Indications And Usage

For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested.Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus.As a sedative when used as a premedication and following general anesthesia,


hydrOXYzine may potentiate meperidine and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis.  Atropine and other belladonna alkaloids are not affected by the drug.  HydrOXYzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent.


The effectiveness of hydrOXYzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies.  The physician should reassess periodically the usefulness of the drug for the individual patient.

Contraindications

Oral hydroxyzine hydrochloride is contraindicated in patients with known hypersensitivity to hydroxyzine hydrochloride products, and in patients with known hypersensitivity to cetirizine hydrochloride or levocetirizine hydrochloride.HydrOXYzine, when administered to the pregnant mouse, rat, and rabbit induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range.  Clinical data in human beings are inadequate to establish safety in early pregnancy.  Until such data are available, hydrOXYzine is contraindicated in early pregnancy.HydrOXYzine is contraindicated for patients who have shown a previous hypersensitivity to it.WARNINGS:  Nursing Mothers:  It is not known whether this drug is excreted in human milk.  Since many drugs are so excreted, hydrOXYzine should not be given to nursing mothers.

Precautions

THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES. Therefore, when central nervous system depressants are administered concomitantly with hydrOXYzine their dosage should be reduced.Since drowsiness may occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery while taking hydrOXYzine.  Patients should also be advised against the simultaneous use of other CNS depressant drugs, and cautioned that the effects of alcohol may be increased.Geriatric Use:  A determination has not been made whether controlled clinical studies of hydrOXYzine included sufficient numbers of subjects aged 65 and over to define a difference in response from younger subjects.  Other reported clinical experience has not identified differences in responses between the elderly and younger patients.  In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.


The extent of renal excretion of hydrOXYzine has not been determined.  Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections.Sedating drugs may cause confusion and over sedation in the elderly; elderly patients generally should be started on low doses of hydrOXYzine and observed closely.

Adverse Reactions

Side effects reported with the administration of hydrOXYzine hydrochloride are usually mild and transitory in nature.Anticholinergic:  Dry mouth.


Central Nervous System:  Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of dose.  Involuntary motor activity including rare instances of tremor and convulsions have been reported, usually with doses considerably higher than those recommended.  Clinically significant respiratory depression has not been reported at recommended doses.


In post-marketing experience, the following additional undesirable effects havebeen reported:Body as a Whole: Allergic reaction.


Nervous System: Headache.


Psychiatric: Hallucination.


Skin and Appendages: Oral hydroxyzine hydrochloride is associated with fixed drug eruptions in postmarketing reports.

Overdosage

The most common manifestation of hydrOXYzine overdosage is hypersedation.  As in the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken.If vomiting has not occurred spontaneously, it should be induced.  Immediate gastric lavage is also recommended.  General supportive care, including frequent monitoring of the vital signs and close observation of the patient, is indicated.  Hypotension, though unlikely, may be controlled with intravenous fluids and levarterenol or metaraminol.  Do not use epinephrine as hydrOXYzine counteracts its pressor action.There is no specific antidote.  It is doubtful that hemodialysis would be of any value in the treatment of overdosage with hydrOXYzine.  However, if other agents such as barbiturates have been ingested concomitantly, hemodialysis may be indicated.  There is no practical method to quantitate hydrOXYzine in body fluids or tissue after its ingestion or administration.

Dosage And Administration

For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested:  Adults, 50-100 mg q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50-100 mg daily in divided doses.For use in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus:  adults, 25 mg t.i.d. or q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50-100 mg daily in divided doses.As a sedative when used as a premedication and following general anesthesia: 50-100 mg for adults and 0.6 mg/kg of body weight in children.When treatment is initiated by the intramuscular route of administration, subsequent doses may be administered orally.As with all potent medication, the dosage should be adjusted according to the patient’s response to therapy.

How Supplied

HydrOXYzine Hydrochloride Tablets, USP,10 mg - Round, white, film-coated tablet, debossed “H 500”, supplied in bottles of 15.Bottles of 15
NDC 66267-112-15
Dispense in a tight container as defined in the USP.Store at controlled room temperature 20°-25°C (68°-77°F); [see USP Controlled Room Temperature].Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.Manufactured for:Heritage Pharmaceuticals Inc.Eatontown, NJ 077241-866-901-DRUG (3784)Iss.06/14

* Please review the disclaimer below.